Navigation Links
Reversing 'hibernating' heart muscle focus of UB researchers

Heart researchers at the University at Buffalo have received a $2.5 million five-year grant to develop new strategies to reverse a heart dysfunction called "hibernating myocardium" that can cause disabling heart failure and sudden death.

Hibernating myocardium is a condition in which myocytes (cells in the heart's muscular tissue) shut down, but remain viable in areas that receive reduced blood flow over an extended period of time due to narrowed arteries. This creates areas of the heart that contract poorly.

The new grant from the National Heart Lung and Blood Institute builds on pioneering work of scientists in UB's Center for Research in Cardiovascular Medicine who developed a novel pig model with hibernating myocardium.

Previous research has shown that, while restoring blood flow to these "hibernating" regions improves function and a patient's prognosis, cells in the left ventricle (the heart's main pumping chamber) often remain chronically dysfunctional and do not return to normal. The reasons for this remain unclear, researchers say, but in most circumstances do not appear to be caused by replacement with scar tissue.

The new grant will allow researchers to determine if the metabolic changes that myocytes undergo in order to remain viable during hibernation limit their long-term ability to recover fully after revascularization.

John M. Canty, M.D., Albert and Elizabeth Rekate Chair in Cardiovascular Disease in the UB School of Medicine and Biomedical Sciences and chief of the Division of Cardiovascular Medicine, is principal investigator on the grant. Canty is a head of the Cardiovascular Disease Group of the New York State Center of Excellence in Bioinformatics and Life Sciences at UB.

The researchers will undertake concurrent physiological, proteomic and mitochondrial functional studies in the swine model that will be translatable to humans. Proteomic profiling will identify candidate mitochondrial proteins in the swine with established viable dysfunctional myocardium that do not have significant cardiac scar tissue.

"These protein studies will be coupled with assays of mitochondrial respiration and of the activity of specific enzymes in the swine model," said Canty.

"This work relies on the state-of-the art proteomic research facilities and mass spectrometry at UB.

"By using therapies similar to those that are used clinically in patients, such as angioplasty and adenoviral gene transfer to over-express growth factors in the heart, we can identify how changes in the molecular pathways responsible for the adaptation to decreased blood flow can be reversed more completely. The ultimate goal of manipulating these pathways will be to restore full contractile function."

Areas of hibernating myocardium are common in patients with heart failure arising from coronary artery disease, Canty noted. "Determining how this impacts prognosis is the focus of the UB Cardiovascular Center's PAREPET (Prediction of Arrhythmic Events with Positron Emission Tomography) clinical trial, which also is funded by NHLBI.

"Identifying the basic mechanisms responsible for incomplete functional recovery after revascularization hopefully will lead to new therapies that will improve the outlook and symptoms of these patients who are at high risk for adverse cardiovascular events," said Canty.

Additional investigators on the study are Alan D. Hutson, Ph.D., professor and chair of the UB Department of Biostatistics; Te-Chung Lee, Ph.D., associate professor of biochemistry; Jun Qu, Ph.D., research assistant professor of pharmaceutics, and Michael D. Banas, M.D., research assistant professor of medicine.

Kenneth Blumenthal, Ph.D., professor and chair of the UB Department of Biochemistry, and Robert Straubinger, Ph.D., associate professor of pharmaceutics, will serve as study consultants.


'"/>

Source:University at Buffalo


Related biology news :

1. Reversing cancer cells to normal cells
2. UCSD team discovers specialized, rare heart stem cells in newborns
3. Single stem cells from bone heal a broken heart
4. Python a hearty eater
5. Columbia study shows widely used artery clearing device does not help patients during heart attack
6. Researchers reveal secret of key protein in brain and heart function
7. Stem cell therapy successfully treats heart attack in animals
8. New defibrillator signals doctor of patients irregular heartbeat or device malfunction
9. Survival of heart patients on beta-blockers varies greatly with genetic variation
10. Chemical band-aid prevents heart failure in mice with muscular dystrophy
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
Breaking Biology Technology: